Cargando…

The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice

Here, we explored the possible interaction between duloxetine and SEP-363856 (SEP-856) in depression-related reactions. The results showed that oral administration of duloxetine showed powerful antidepressant-like effects in both the forced swimming test (FST) and the suspension tail test (TST). SEP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Xia, Xiong, Jiaying, Liang, Lingzhi, Chen, Yin, Zhang, Guisen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105920/ https://www.ncbi.nlm.nih.gov/pubmed/35566106 http://dx.doi.org/10.3390/molecules27092755

Ejemplares similares

Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia
por: Liang, Lingzhi, et al.
Publicado: (2022)

TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP-363856
por: Saarinen, Marcus, et al.
Publicado: (2022)

Correction To: TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP- 363856
por: Saarinen, Marcus, et al.
Publicado: (2022)

Effect of TAAR1/5-HT(1A) agonist SEP-363856 on REM sleep in humans
por: Hopkins, Seth C., et al.
Publicado: (2021)

In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics
por: Ågren, Richard, et al.
Publicado: (2023)

M208. MEASURES OF COGNITION AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS RECEIVING SEP-363856
por: Milanovic, Snezana, et al.
Publicado: (2020)

Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856
por: Begni, Veronica, et al.
Publicado: (2021)

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
por: Correll, Christoph U., et al.
Publicado: (2021)

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia
por: Heffernan, Michele L. R., et al.
Publicado: (2021)

Structural and Functional Evolution of the Trace Amine-Associated Receptors TAAR3, TAAR4 and TAAR5 in Primates
por: Stäubert, Claudia, et al.
Publicado: (2010)

The Combination of Antidepressant Duloxetine with Piracetam in Mice does not Produce Enhancement of Nootropic Activity
por: Kale, Pravin Popatrao, et al.
Publicado: (2014)

Identification and characterization of cichlid TAAR genes and comparison with other teleost TAAR repertoires
por: Azzouzi, Naoual, et al.
Publicado: (2015)

Analysis of Human TAAR8 and Murine Taar8b Mediated Signaling Pathways and Expression Profile
por: Mühlhaus, Jessica, et al.
Publicado: (2014)

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
por: Achtyes, Eric D., et al.
Publicado: (2023)

The Antidepressant Duloxetine Inhibits Platelet Function and Protects against Thrombosis
por: Lozano, Patricia A., et al.
Publicado: (2022)

Search for Structural Basis of Interactions of Biogenic Amines with Human TAAR1 and TAAR6 Receptors
por: Glyakina, Anna V., et al.
Publicado: (2021)

Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies
por: Dedic, Nina, et al.
Publicado: (2021)

Taare Zameen Par and dyslexic savants
por: Chakravarty, Ambar
Publicado: (2009)

Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397
por: Espinoza, Stefano, et al.
Publicado: (2018)

Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment
por: Wang, Yunjie, et al.
Publicado: (2023)

Dynamic Stability of Volatile Organic Compounds in Respiratory Air in Schizophrenic Patients and Its Potential Predicting Efficacy of TAAR Agonists
por: Held, Anna, et al.
Publicado: (2023)

Evaluation of Approach to a Conspecific and Blood Biochemical Parameters in TAAR1 Knockout Mice
por: Zhukov, Ilya S., et al.
Publicado: (2022)

TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg
por: Liu, Jian-Feng, et al.
Publicado: (2018)

New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection
por: Bellusci, Lorenza, et al.
Publicado: (2017)

In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT(1A) Receptor Agonist for the Treatment of Schizophrenia
por: Xiao, Guangqing, et al.
Publicado: (2022)

Discovery of Guanfacine as a Novel TAAR1 Agonist: A Combination Strategy through Molecular Modeling Studies and Biological Assays
por: Cichero, Elena, et al.
Publicado: (2023)

Behavioral Effects of a Potential Novel TAAR1 Antagonist
por: Lam, Vincent M., et al.
Publicado: (2018)

Improving Efficiency and Equity in Early Autism Evaluations: The (S)TAAR Model
por: Brinster, Meredith I., et al.
Publicado: (2022)

Effects of the antidepressant medication duloxetine on brain metabolites in persistent depressive disorder: A randomized, controlled trial
por: Bansal, Ravi, et al.
Publicado: (2019)

Improved cognitive performance in trace amine-associated receptor 5 (TAAR5) knock-out mice
por: Maggi, Silvia, et al.
Publicado: (2022)

Enhancement of nootropic effect of duloxetine and bupropion by caffeine in mice
por: Kale, Pravin Popatrao, et al.
Publicado: (2015)

Tumor growth activity of duloxetine in Ehrlich carcinoma in mice
por: Moura, Ed Carlos Rey, et al.
Publicado: (2018)

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS
por: Hopkins, Seth C., et al.
Publicado: (2021)

Pharmacokinetics of duloxetine self-administered in overdose with quetiapine and other antipsychotic drugs in a Japanese patient admitted to hospital
por: Adachi, Koichiro, et al.
Publicado: (2021)

Investigation of Naturally Occurring Single-Nucleotide Variants in Human TAAR1
por: Mühlhaus, Jessica, et al.
Publicado: (2017)

The Case for TAAR1 as a Modulator of Central Nervous System Function
por: Rutigliano, Grazia, et al.
Publicado: (2018)

Review and Meta-Analyses of TAAR1 Expression in the Immune System and Cancers
por: Fleischer, Lisa M., et al.
Publicado: (2018)

Cine difusión Sep
Publicado: (1975)

Minor Changes in Erythrocyte Osmotic Fragility in Trace Amine-Associated Receptor 5 (TAAR5) Knockout Mice
por: Zhukov, Ilya S., et al.
Publicado: (2021)

Duloxetine hydrochloride
por: Bhadbhade, Mohan, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_tjgkaoqo00h0ofem2fjgg9e8rf